We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > sitravatinib

News List

Mirati Announces Executive Management Changes americanpharmaceuticalreview
January 09, 2020
Mirati Therapeutics has announced changes to their executive management team, effective immediately. Mirati continues to accelerate the development of the KRAS and sitravatinib programs ...
Mirati Announces Collaboration with Bristol-Myers Squibb for Sitravatinib, OPDIVO Trial americanpharmaceuticalreview
January 09, 2019
Mirati Therapeutics announced a clinical collaboration with Bristol-Myers Squibb Company to evaluate the combination of sitravatinib and nivolumab (OPDIVO)....
First Patient Dosed in Trial of Sitravatinib in Combination with Tislelizumab americanpharmaceuticalreview
November 13, 2018
First Patient Dosed in Trial of Sitravatinib in Combination with Tislelizumab
Shares in Mirati plummet after disappointing Phase II trial pharmafile
November 01, 2018
Shares in the California-based biotech Mirati Therapuetics plummeted on Monday after the company released disappointing results from their Phase II study of the experimental drug sitravatinib...